Hypertension in the Cardio-Oncology Clinic

Heart Fail Clin. 2019 Oct;15(4):487-495. doi: 10.1016/j.hfc.2019.06.010.

Abstract

As cancer therapies improve, the population of survivors of cancer has increased, and the long-term effects of cancer treatments have become more apparent. Cardiotoxicity is a well-established adverse effect of many antineoplastic agents. Hypertension is common in survivors of cancer, can be caused or worsened by certain agents, and has been shown to increase the risk of other cardiovascular diseases including heart failure. Pretreatment risk assessment and careful monitoring of blood pressure during therapy is essential. Aggressive management of preexisting or incident hypertension in survivors of cancer is paramount to decrease the risk of heart failure and other cardiovascular diseases in these patients.

Keywords: Cardio-oncology; Cardiotoxicity; Heart failure; Hypertension; Vascular endothelial growth factor signaling pathway inhibitor.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Antineoplastic Agents* / therapeutic use
  • Cardiotoxicity* / diagnosis
  • Cardiotoxicity* / prevention & control
  • Drug Monitoring
  • Heart Failure* / etiology
  • Heart Failure* / prevention & control
  • Humans
  • Hypertension* / diagnosis
  • Hypertension* / drug therapy
  • Hypertension* / etiology
  • Neoplasms / therapy*
  • Risk Adjustment / methods*

Substances

  • Antineoplastic Agents